Last reviewed · How we verify

Etoposide, carboplatin, melphalan, cisplatin, thiotepa — Competitive Intelligence Brief

Etoposide, carboplatin, melphalan, cisplatin, thiotepa (Etoposide, carboplatin, melphalan, cisplatin, thiotepa) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: alkylating agents. Area: Oncology.

phase 2 alkylating agents Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Etoposide, carboplatin, melphalan, cisplatin, thiotepa (Etoposide, carboplatin, melphalan, cisplatin, thiotepa) — Gustave Roussy, Cancer Campus, Grand Paris. Etoposide, carboplatin, melphalan, cisplatin, and thiotepa are chemotherapeutic agents that work by interfering with DNA replication and cell division, ultimately leading to cell death.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Etoposide, carboplatin, melphalan, cisplatin, thiotepa TARGET Etoposide, carboplatin, melphalan, cisplatin, thiotepa Gustave Roussy, Cancer Campus, Grand Paris phase 2 alkylating agents
Busulfan/Cyclophosphamide Busulfan/Cyclophosphamide Tel-Aviv Sourasky Medical Center marketed Alkylating agents
PCV chemotherapy PCV chemotherapy Hospices Civils de Lyon phase 3 Chemotherapy regimen (alkylating agents + vinca alkaloid)
Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan Dutch Childhood Oncology Group phase 3 Multi-agent chemotherapy regimen; alkylating agents, antimetabolite, topoisomerase II inhibitor
Busulphan plus Cyclophosphamide Busulphan plus Cyclophosphamide Gruppo Italiano Trapianto di Midollo Osseo phase 3 Alkylating agents
Fludarabine, OKT3, Treosulfan, Thiotepa Fludarabine, OKT3, Treosulfan, Thiotepa St. Anna Kinderkrebsforschung phase 3 Multi-agent conditioning regimen (purine analog, monoclonal antibody, alkylating agents) dTMP synthase (fludarabine); CD3 (OKT3); DNA (treosulfan, thiotepa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (alkylating agents class)

  1. Gustave Roussy, Cancer Campus, Grand Paris · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Etoposide, carboplatin, melphalan, cisplatin, thiotepa — Competitive Intelligence Brief. https://druglandscape.com/ci/etoposide-carboplatin-melphalan-cisplatin-thiotepa. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: